Sarbani Maitra, MD
Psychiatry · Fairfield, CANPI 1134360647
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,500 of the $13,491 with a category attached, or 70.4%. 18 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 24.1% of the total. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $40.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Alkermes, Inc.$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$802
- plus $3K from 12 others
Across 297 payments — averaging $10,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$1.9M
- AbbVie$677K
- Janssen Research & Development, LLC$240K
- Boehringer Ingelheim$209K
- Siemens Medical Solutions USA, Inc.$48K
- Neurocrine Biosciences, Inc.$32K
- plus $11K from 2 others
What the payments were for
- Travel & lodging$3,81828%
- Food & beverage$9,50070%
- Education$1721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 41 | $3,252 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $2,215 |
| Alkermes, Inc. | 58 | $1,557 |
| AbbVie | 53 | $1,324 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,320 |
| E.r. Squibb & Sons, L.L.C. | 15 | $802 |
| Vanda Pharmaceuticals Inc. | 22 | $650 |
| Otsuka America Pharmaceutical, Inc. | 19 | $492 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $341 |
| Axsome Therapeutics, Inc. | 10 | $306 |
| Lundbeck LLC | 13 | $281 |
| Indivior Inc. | 10 | $274 |
| Johnson & Johnson | 10 | $271 |
| Sunovion Pharmaceuticals Inc. | 9 | $162 |
| Bioxcel Therapeutics, Inc. | 2 | $116 |
| Bausch Health US, LLC | 3 | $66 |
| Neuronetics, Inc. | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,000
- LYBALVI$464
- COBENFY$381
- AUSTEDO$256
- ARISTADA INITIO$250
- VRAYLAR$249
- INGREZZA$236
- ABILIFY MAINTENA$125
- Austedo XR$124
- CAPLYTA$122
- Fanapt$121
How this compares
$13,491 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 16 | $216,860 |
| Invega SustennaPaliperidone Palmitate | 60 | $194,875 |
| Invega TrinzaPaliperidone Palmitate | 12 | $116,843 |
| Abilify MaintenaAripiprazole | 27 | $77,817 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $46,286 |
| Clozapine | 76 | $6,023 |
| Asenapine Maleate | 11 | $2,731 |
| Fluphenazine Hcl | 15 | $1,419 |
| Olanzapine | 73 | $1,139 |
| Divalproex Sodium ErDivalproex Sodium | 57 | $1,126 |
| Risperidone | 74 | $998 |
| Gabapentin | 50 | $752 |
| Prazosin Hcl | 20 | $630 |
| Aripiprazole | 18 | $542 |
| AmantadineAmantadine Hcl | 15 | $462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $271 | $311,71872 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,320 | $216,86016 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $492 | $77,81727 claims |
| Alkermes, Inc.Lybalvi | $1,557 | $46,28624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Fairfield
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.